📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-13 16:55
538 analysed today
FollowTelegram
538
Today
149,939
All-time analysed
42,983
Positive
6,669
Negative
91,579
Neutral
8,640
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
6 announcements match the current filters (relevance ≥ 5).
Achyut Healthcare Approves Q1 FY27 Results; TTM Revenue at Rs 9 Cr
Achyut Healthcare approved its unaudited financial results for the quarter ended June 30, 2026, in a board meeting held on August 13, 2026. The company continues to operate in a single segment (Pharmaceuticals) amid a challenging environment where previous annual revenue fell 50.34% due to intense competition. With a TTM revenue of just Rs 9 Cr and a high P/E of 352.5, the company's core trading business remains under significant margin pressure. The board meeting was brief, lasting 40 minutes to conclude the approval process.
Confidence: MEDIUM
What changedThe company has finalized and approved its financial performance report for the first quarter of the 2026-27 fiscal year.
Why it mattersFor a micro-cap company with a high valuation relative to its small revenue base (Rs 9 Cr TTM), quarterly results are the primary indicator of whether the business can sustain its market cap through core operations rather than non-operating income.
TTM Revenue: Rs 9 CrMarket Cap: Rs 106 CrP/E Ratio: 352.5TTM OPM: 1.5%Revenue vs Market Cap: 8.49%
📅 Short termThe stock may remain range-bound as the market evaluates the core profitability against the high valuation multiples.
📈 Long termLimited structural significance unless the company demonstrates a clear strategy to counter competition from larger pharma players and improves its operating margins.
⚠ Risk flags
- High valuation (P/E 352.5)
- Low operating margins (1.5%)
- Intense competition from large pharmaceutical companies
- Small scale of operations (TTM Revenue Rs 9 Cr)
Key Highlights
Board meeting concluded in 40 minutes (16:00 to 16:40) on August 13, 2026
Company operates exclusively in the Pharmaceuticals Business segment
TTM revenue stands at Rs 9 Cr against a market capitalization of Rs 106 Cr
Operating margins remain thin at 1.5% based on TTM data
Promoter holding remains stable at 47.4% as of the latest reporting period
👀 What to Watch
Investors should scrutinize the full P&L for signs of recovery in operating EBITDA, which previously collapsed to -6.63% YoY. Monitor if the company can scale its trading volume to justify the current P/E of 352.5.
Achyut Healthcare Approves Q1 FY27 Results; TTM Revenue Stands at Rs 9 Cr
Achyut Healthcare's board met on August 13, 2026, to approve the unaudited financial results for the quarter ended June 30, 2026. While the specific P&L figures for the quarter were not detailed in the provided document extract, the company continues to operate in a single segment: Pharmaceuticals. The company faces significant headwinds with a TTM operating margin of just 1.5% and a high P/E ratio of 352.5. Investors should note the company's small scale, with TTM revenue at approximately Rs 9 Cr against a market capitalization of Rs 106 Cr.
Confidence: MEDIUM
What changedThe company has formally approved its financial performance report for the first quarter of the 2026-27 fiscal year.
Why it mattersAs a small-cap pharma trader with thin margins, quarterly results are critical to determine if the business can scale or if it remains reliant on non-operating income for profitability.
TTM Revenue: Rs 9 CrMarket Cap: Rs 106 CrTTM OPM: 1.5%P/E Ratio: 352.5Meeting Duration: 40 minutes
📅 Short termNeutral, as the market will wait for the detailed P&L figures to assess the trajectory of the core trading business.
📈 Long termLimited, given the lack of a sustainable moat and intense competition from larger pharmaceutical companies as noted in management's previous strategy disclosures.
⚠ Risk flags
- Extremely high P/E ratio (352.5)
- Very low operating margins (1.5%)
- High competition in the pharmaceutical trading segment
Key Highlights
Board approved unaudited financial results for the quarter ended June 30, 2026
The board meeting was conducted within a 40-minute window (16:00 to 16:40)
Company maintains a single reportable segment in the Pharmaceuticals Business
TTM Revenue is currently Rs 9 Cr, reflecting a small-scale trading operation
Operating Profit Margin (OPM) remains thin at 1.5% based on TTM data
👀 What to Watch
Investors should examine the full financial statement to check if the 50.34% revenue decline seen in previous periods has been arrested and if operating margins have improved beyond the current 1.5%.
119:50 Swap Ratio: Achyut Healthcare to Merge into Zenith Healthcare Ltd
Achyut Healthcare (Transferor) has approved a Scheme of Amalgamation to merge into Zenith Healthcare Ltd (Transferee), a fellow group company. Shareholders of Achyut will receive 119 shares of Zenith (FV ₹1) for every 50 shares of Achyut (FV ₹1) held. Financially, Achyut is the larger entity with a net worth of ₹35.06 cr compared to Zenith's ₹7.42 cr as of March 2026. The merger aims to consolidate pharmaceutical trading and manufacturing operations, resulting in the promoter stake in Zenith rising from 28.74% to 45.80%.
Confidence: HIGH
What changedAchyut Healthcare is merging into Zenith Healthcare, effectively consolidating two group entities into a single listed pharmaceutical company.
Why it mattersThe merger combines Achyut's stronger balance sheet (4.7x the net worth of Zenith) with Zenith's manufacturing expertise, potentially creating a more robust entity with streamlined compliance and operational synergies.
Swap Ratio: 119:50Achyut Net Worth (Mar 2026): ₹35.06 crZenith Net Worth (Mar 2026): ₹7.42 crPost-Merger Promoter Stake: 45.80%Achyut FY26 Turnover: ₹11.97 cr
📅 Short termThe stock price may adjust to reflect the swap ratio; however, the merger is subject to several regulatory approvals which may take months.
📈 Long termThe combined entity will have a unified balance sheet and access to Achyut's new manufacturing facility, which could improve market opportunities in regulated pharma markets.
⚠ Risk flags
- Related party transaction (same promoter group)
- Regulatory approval risk (NCLT and SEBI)
- Dilution of public shareholding in the transferee company
Key Highlights
Share exchange ratio fixed at 119 Zenith shares for every 50 Achyut shares held.
Achyut Healthcare reported a net worth of ₹35.06 cr and turnover of ₹11.97 cr for FY26.
Zenith Healthcare reported a net worth of ₹7.42 cr and turnover of ₹10.94 cr for FY26.
Post-merger promoter shareholding in Zenith will increase significantly to 45.80% from 28.74%.
Achyut Healthcare will be dissolved without winding up upon the scheme becoming effective.
👀 What to Watch
Investors should monitor the timeline for NCLT (National Company Law Tribunal) approval and the upcoming shareholder meeting where a majority of public shareholders must approve the scheme.
119:50 Swap Ratio: Achyut Healthcare to Merge into Zenith Healthcare Ltd
Achyut Healthcare Ltd has approved a Scheme of Amalgamation to merge into Zenith Healthcare Ltd, a related party under the same promoter group. Shareholders of Achyut will receive 119 shares of Zenith (FV ₹1) for every 50 shares of Achyut (FV ₹1) held. Achyut brings a significantly larger balance sheet with a net worth of ₹35.06 cr compared to Zenith's ₹7.42 cr as of March 2026. Post-merger, the promoter holding in the combined Zenith entity will increase from 28.74% to 45.80%.
Confidence: HIGH
What changedAchyut Healthcare will be dissolved without winding up, and its entire business will be absorbed by Zenith Healthcare Ltd.
Why it mattersThis is a consolidation of two pharma entities under the same promoter group to create a larger unified balance sheet and integrate Achyut's new manufacturing capacity with Zenith's existing marketing and export network.
Share Swap Ratio: 119:50Achyut Net Worth (Mar 2026): ₹3506.12 lakhsZenith Net Worth (Mar 2026): ₹742.42 lakhsPost-Merger Promoter Stake: 45.80%Achyut FY26 Turnover: ₹1197.15 lakhs
📅 Short termThe stock may see volatility as the market adjusts to the swap ratio and the significant increase in promoter holding in the surviving entity.
📈 Long termStructural consolidation could improve operational efficiency and financial flexibility, especially for the commissioning of the new EU-GMP compliant plant.
⚠ Risk flags
- Related party transaction
- Significant dilution for Zenith's public shareholders (71.26% to 54.20%)
- Regulatory approval risk from NCLT and SEBI
Key Highlights
Swap ratio fixed at 119 Zenith Healthcare shares for every 50 Achyut Healthcare shares.
Achyut Healthcare's net worth of ₹35.06 cr is approximately 4.7x larger than Zenith's ₹7.42 cr.
Combined entity promoter stake to rise significantly to 45.80% from Zenith's current 28.74%.
Achyut reported FY26 turnover of ₹11.97 cr, while Zenith reported ₹10.94 cr for the same period.
Merger aims to leverage Achyut's upcoming EU-GMP certified manufacturing facility in Ahmedabad.
👀 What to Watch
Monitor the NCLT approval process and the upcoming e-voting where public shareholders must approve the scheme; track the timeline for the record date which will determine eligibility for Zenith shares.
119:50 Share Swap: Achyut Healthcare to Merge into Zenith Healthcare Ltd
Achyut Healthcare (Transferor) has approved a scheme of amalgamation to merge into Zenith Healthcare (Transferee), both being part of the same promoter group. Shareholders of Achyut will receive 119 equity shares of Zenith (FV ₹1) for every 50 shares held in Achyut (FV ₹1). Achyut brings a significantly larger balance sheet with a net worth of ₹35.06 cr compared to Zenith's ₹7.42 cr as of March 2026. The merger aims to consolidate pharmaceutical trading and manufacturing operations, with promoter holding in the combined entity set to rise to 45.80%.
Confidence: HIGH
What changedAchyut Healthcare will be dissolved and its business integrated into Zenith Healthcare, consolidating two group companies into a single listed entity.
Why it mattersThe merger combines Achyut's stronger financial position and upcoming manufacturing capacity with Zenith's established manufacturing expertise and market presence, creating a more robust pharmaceutical player.
Share Exchange Ratio: 119:50Achyut Net Worth (Mar-26): ₹3506.12 lakhsZenith Net Worth (Mar-26): ₹742.42 lakhsPost-Merger Promoter Holding: 45.80%Achyut TTM Turnover: ₹1197.15 lakhs
📅 Short termThe stock may see volatility as the market adjusts to the swap ratio and the valuation of the two entities.
📈 Long termStructural consolidation could lead to better operational efficiency and a stronger balance sheet for future expansions, provided the new manufacturing facility is successfully commissioned.
⚠ Risk flags
- Related-party transaction
- Regulatory approval risks (NCLT, SEBI)
- Execution risk of the new manufacturing facility
Key Highlights
Share exchange ratio fixed at 119 Zenith shares for every 50 Achyut shares held.
Achyut Healthcare reported a turnover of ₹11.97 cr and net worth of ₹35.06 cr for FY26.
Zenith Healthcare reported a turnover of ₹10.94 cr and net worth of ₹7.42 cr for FY26.
Combined entity promoter holding will increase from 28.74% to 45.80% post-merger.
Achyut is currently developing a new EU-GMP compliant manufacturing facility in Ahmedabad.
👀 What to Watch
Monitor the timeline for NCLT and shareholder approvals, and track the progress of Achyut's new manufacturing facility which is a key rationale for the merger.
119:50 Swap Ratio: Achyut Healthcare to Merge into Zenith Healthcare
Achyut Healthcare (Transferor) has approved a merger into Zenith Healthcare (Transferee), both being listed entities under the same promoter group. Shareholders of Achyut will receive 119 shares of Zenith (FV ₹1) for every 50 shares of Achyut (FV ₹1) held. Achyut is significantly larger than the surviving entity, with a net worth of ₹35.06 cr compared to Zenith's ₹7.42 cr as of March 2026. Post-merger, the promoter stake in Zenith will increase from 28.74% to 45.80%, and the total share capital will expand from 5.37 cr to 62.82 cr shares.
Confidence: HIGH
What changedAchyut Healthcare will be dissolved without winding up, and its entire business, assets, and liabilities will be transferred to Zenith Healthcare.
Why it mattersThis is a major consolidation of group companies that creates a larger balance sheet and combines Achyut's API trading and new manufacturing capacity with Zenith's existing pharmaceutical export business.
Swap Ratio (Zenith:Achyut): 119:50Achyut Net Worth (Mar-26): ₹3506.12 lakhsZenith Net Worth (Mar-26): ₹742.42 lakhsPost-Merger Promoter Stake: 45.80%Total Post-Merger Shares: 62,81,68,660
📅 Short termThe market will likely adjust the stock prices of both entities to align with the 2.38x swap ratio. Expect volatility as arbitrageurs and long-term investors digest the valuation.
📈 Long termThe merger aims for operational synergies and a stronger balance sheet to fund future expansions, particularly Achyut's new GMP-compliant manufacturing facility.
⚠ Risk flags
- Regulatory approval risk (NCLT, SEBI, Shareholders)
- Related-party transaction (same promoter group)
- Significant equity dilution for existing Zenith public shareholders
Key Highlights
Share exchange ratio fixed at 119 Zenith shares for every 50 Achyut shares held.
Achyut Healthcare's net worth of ₹35.06 cr is approximately 4.7x larger than Zenith's ₹7.42 cr.
Combined entity's total equity base will expand significantly to 62.81 cr shares from Zenith's current 5.37 cr.
Promoter holding in the surviving entity (Zenith) will rise to 45.80% from the current 28.74%.
Achyut reported a TTM turnover of ₹11.97 cr, while Zenith reported ₹10.94 cr for the same period.
👀 What to Watch
Monitor the NCLT approval process and the announcement of the record date for the share swap. Investors should evaluate the combined entity's ability to operationalize Achyut's new manufacturing facility currently under commissioning.
